49 related articles for article (PubMed ID: 22825324)
21. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
[TBL] [Abstract][Full Text] [Related]
22. Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media.
Iino Y; Usubuchi H; Kodama K; Kanazawa H; Takizawa K; Kanazawa T; Ohta Y
Otol Neurotol; 2010 Jan; 31(1):100-4. PubMed ID: 19816234
[TBL] [Abstract][Full Text] [Related]
23. Antigen-specific IgE in middle ear effusion of patients with eosinophilic otitis media.
Kanazawa H; Yoshida N; Shinnabe A; Iino Y
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):88-92. PubMed ID: 24863399
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
25. Eosinophilic Otitis Media Treated with Anti-IgE Monoclonal Antibodies and A Bone Conduction Implant.
Han YE; Kang YS; Cho Y; Park MK
J Int Adv Otol; 2018 Apr; 14(1):144-147. PubMed ID: 29764789
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Otol Neurotol; 2012 Sep; 33(7):1218-24. PubMed ID: 22825324
[TBL] [Abstract][Full Text] [Related]
27. Role of IgE in eosinophilic otitis media.
Iino Y
Allergol Int; 2010 Sep; 59(3):233-238. PubMed ID: 20657163
[TBL] [Abstract][Full Text] [Related]
28. Eosinophilic otitis media: a new middle ear disease entity.
Iino Y
Curr Allergy Asthma Rep; 2008 Nov; 8(6):525-30. PubMed ID: 18940145
[TBL] [Abstract][Full Text] [Related]
29. New Insights into Eosinophilic Otitis Media.
Kanazawa H; Yoshida N; Iino Y
Curr Allergy Asthma Rep; 2015 Dec; 15(12):76. PubMed ID: 26546407
[TBL] [Abstract][Full Text] [Related]
30. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
31. Use of IL-5 Inhibitor Benralizumab as a Novel Therapy for Eosinophilic Otitis Media: Clinical Capsule and Review of Literature.
Chow K; Cosetti MK
Otol Neurotol; 2020 Feb; 41(2):e238-e240. PubMed ID: 31923159
[TBL] [Abstract][Full Text] [Related]
32. Omalizumab beyond asthma.
Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
[TBL] [Abstract][Full Text] [Related]
33. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
[TBL] [Abstract][Full Text] [Related]
34. Eosinophilic otitis media; state-of-the-art diagnosis and treatment.
Iino Y
Auris Nasus Larynx; 2023 Aug; 50(4):479-489. PubMed ID: 36528403
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
